Does Ketamine Work for Depression? Evidence, Limits, and Treatment Decisions
Ketamine has scientific evidence for reducing depressive symptoms in some patients, including adults with treatment-resistant depression. That is different from saying it works for everyone, provides a lasting cure, or has the same evidence in every formulation. The answer to “Does ketamine work for depression?” depends on the patient group, route, comparison treatment, and outcome being discussed.
For someone considering ketamine therapy for depression, the useful question is not simply whether ketamine is promising. It is whether the evidence supports the exact intervention being proposed for your situation, and whether its potential benefits outweigh its risks and practical burdens.
First, separate ketamine from Spravato
The FDA's explanation of ketamine and esketamine products makes an important distinction: racemic ketamine is approved as an anesthetic, not for psychiatric disorders. Its use for depression is off-label. Spravato is a specific branded esketamine nasal spray with adult depression indications and its own safety requirements.
Off-label does not mean that no research exists. It means the proposed use is not included in the medication's FDA approval. Conversely, approval of Spravato does not transfer to an intravenous ketamine service or a compounded nasal spray.
Ask for the product and route before reviewing a claimed success rate. A study of supervised intravenous ketamine does not establish identical benefit for every take-home or compounded preparation. Similar names and related molecules are not enough to make those treatments interchangeable.
Ketamine vs. ECT: what does a controlled depression trial show?
The 2023 ELEKT-D randomized trial compared intravenous ketamine with electroconvulsive therapy, or ECT, in people referred to ECT clinics for treatment-resistant major depression without psychosis. It used an initial three-week treatment phase and was open-label, meaning treatment allocation was known.
The reported response rates were 55.4% with ketamine and 41.2% with ECT. Response meant at least a 50% reduction on the study's self-reported depression scale; it did not mean everyone had reached remission. The trial met its prespecified criterion for ketamine to be noninferior to ECT under those conditions.
This is meaningful evidence for a particular clinical situation. It does not establish that ketamine is superior to every ECT protocol, appropriate for psychotic depression, or better than all oral antidepressants. The patients, study design, treatment course, and endpoint must remain attached to the conclusion.
A clinic should explain how closely your history resembles the people studied, rather than presenting the response percentage as your personal probability of recovery.
What about rapid changes in suicidal thoughts?
A randomized trial published in 2018 studied 80 adults with major depression and clinically significant suicidal ideation. At 24 hours, adjunctive intravenous ketamine produced a greater reduction in suicidal-thought scores than midazolam. The study's response threshold was reached by 55% in the ketamine group and 30% in the comparison group.
That result concerns a short-term change in measured thoughts, not demonstrated prevention of suicide deaths. Later improvement occurred during uncontrolled follow-up with additional optimized standard medication treatment, so it should not be described as proof of a lasting effect from ketamine alone.
No one should delay urgent assessment while arranging a ketamine appointment. Research on rapid symptom change does not turn a routine outpatient booking into emergency care. Current safety needs, appropriate monitoring, and continuity of treatment remain essential.
Watch the video: Ketamine as a Treatment for Depression? (Healthcare Triage)
How effective is ketamine for depression over time?
The NIMH medication guide notes that conventional antidepressants usually take several weeks to work. Some ketamine studies assess changes much sooner. However, those differing timelines do not establish that the faster-acting intervention is the best option for every patient.
Ask whether a result describes early improvement, response, remission, or sustained benefit. A change during the first day is not equivalent to remaining well months later. You also need to know how often treatment may be repeated and what evidence supports the proposed continuation plan.
Do not compare percentages pulled from unrelated trials as though they were a head-to-head contest. Differences in previous treatment, symptom severity, other medicines, and follow-up can change the meaning of the numbers. A good evidence discussion explains those differences instead of hiding them.
Who should consider an assessment—not an automatic prescription?
An evaluation should begin with the diagnosis, current symptoms, previous treatments, and safety needs. Bring medication names, approximate treatment dates, benefits, adverse effects, and the kind of psychotherapy you have received. An incomplete history is something to reconstruct, not a reason to guess.
The clinician should review medical conditions, other prescribed or non-prescribed substances, prior reactions, and concerns that could affect treatment. Do not conceal relevant information to improve your chances of receiving a particular intervention. Appropriate screening may lead to a different recommendation.
Also ask which established options remain reasonable. A treatment being available does not mean it should be the next step. Your preferences, access to care, ability to attend appointments, and the burden of monitoring and transport belong alongside evidence and clinical judgment.
Safety requirements depend on the exact product
For Spravato, the current prescribing information requires supervised administration and at least two hours of post-treatment monitoring. It highlights sedation, dissociation, respiratory depression, blood-pressure increases, and potential abuse or misuse. It also states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated.
These are product-specific requirements and limitations. Do not assume that another ketamine service follows the same program simply because its marketing uses similar language. Ask who monitors you, what they monitor, how concerning reactions are handled, and who is responsible for follow-up.
A stronger altered-perception experience is not the treatment goal or proof of greater benefit. Do not independently increase treatment, add substances, or seek medication outside the agreed plan. Report limited benefit, difficult adverse effects, or concerns about use honestly.
Turn the evidence into useful consultation questions
Begin with: “What evidence supports this exact product and route for my diagnosis?” Ask whether the quoted outcome reflects people who began treatment, only those who completed it, or a selected group of prior responders.
Then ask how progress will be measured. Identify symptoms and daily-life goals that matter to you, and agree when benefits and adverse effects will be reviewed. A plan should allow reassessment when treatment is not helping enough; it should not depend on you reporting improvement because you have already paid.
Finally, clarify the practical details: total visit time, transport, expected costs, possible ongoing appointments, communication with existing clinicians, and help between visits. The value of a treatment is not captured by one research percentage when the surrounding care is unclear.
Discussing depression treatment with Sophroneo
Sophroneo Behavioral Health & TMS offers depression care and therapy and counseling at its Powder Springs and Marietta locations in the Atlanta area. Contact Sophroneo to discuss your history and confirm appropriate services, treatment products, routes, and locations. This article does not imply that every route studied in research is offered by the practice.
Frequently asked questions
Does off-label ketamine mean there is no evidence for depression?
No. Controlled studies have investigated psychiatric uses. Off-label describes approval status, not the absence of all research. The important question is how strong and relevant the evidence is for the specific treatment being proposed, and how risks are managed.
Does a rapid improvement mean I will remain well?
Not necessarily. Early improvement and sustained recovery are different outcomes. Ask about follow-up, maintenance evidence, and what happens if symptoms return. Do not interpret the first session as a complete test of every future treatment decision.
Can I apply an intravenous ketamine study to a compounded spray?
Not automatically. Formulation, route, dose selected by the clinician, setting, and patient population can differ. Request evidence for the actual intervention rather than assuming all ketamine-related products produce the same result.
In the United States, call or text 988 for emotional crisis support or suicidal thoughts. Call 911 for immediate danger or a life-threatening emergency. Do not wait for a ketamine or Spravato appointment when urgent care is needed.
This article is educational and reviews selected evidence. It is not an individual prescribing recommendation, proof of eligibility, or a complete systematic review.
Comments